The HER2 status significantly differed between the primary and recurrent tumour in 191 cases (37.3%; K = 0.468, 95%CI 0.400–0.536), a majority of which (n = 157; 82.2%) were either HER2-negative, or HER2-low at diagnosis. The gene discussed is ERBB2; the disease is neoplasm.